Table 3 Baseline characteristics.
From: Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma
Variables | HIV(+) TACE (−) (n = 21) | HIV (−) TACE (+) (n = 42) | P value | HIV(−)TACE(−) (n = 42) | P value |
|---|---|---|---|---|---|
Age (mean ± SD, years) | 50.24 ± 12.10 | 48.38 ± 12.25 | 0.570 | 50.25 ± 12.20 | 0.997 |
Male (%) | 16(76.2%) | 31(73.8%) | 0.838 | 35(83.3%) | 0.734 |
BMI ( mean ± SD, kg/m2) | 22.30 ± 2.17 | 22.33 ± 2.18 | 0.103 | 22.06 ± 1.50 | 0.618 |
HBsAg ( ±) | 15(71.4%) | 33(78.6%) | 0.530 | 32(76.2%) | 0.682 |
Child–Pugh score (mean ± SD) | 5.52 ± 0.60 | 5.64 ± 0.76 | 0.534 | 5.45 ± 0.71 | 0.693 |
TB (mean ± SD, μmol/L) | 16.60 ± 7.95 | 16.75 ± 8.12 | 0.946 | 18.29 ± 7.69 | 0.420 |
HB (mean ± SD, g/dl) | 126.81 ± 28.00 | 124.88 ± 21.79 | 0.765 | 129.24 ± 22.19 | 0.709 |
WBC (mean ± SD ,109/L) | 6.42 ± 0.95 | 6.01 ± 2.40 | 0.335 | 6.54 ± 1.68 | 0.723 |
CRE (mean ± SD, μmol/L) | 65.73 ± 25.54 | 63.62 ± 11.96 | 0.722 | 68.98 ± 15.30 | 0.531 |
ALT (mean ± SD, u/L) | 44.52 ± 28.86 | 39.52 ± 27.24 | 0.503 | 45.88 ± 49.62 | 0.908 |
AST mean ± SD, u/L) | 63.05 ± 49.00 | 62.71 ± 101.82 | 0.989 | 69.29 ± 73.83 | 0.728 |
Plt (mean ± SD, 109/L) | 106.19 ± 51.80 | 109.76 ± 57.07 | 0.810 | 106.40 ± 51.20 | 0.988 |
PT (mean ± SD, s) | 13.74 ± 1.11 | 13.32 ± 3.34 | 0.577 | 13.37 ± 1.44 | 0.310 |
Alb (mean ± SD, g/L) | 37.96 ± 4.31 | 37.01 ± 6.28 | 0.537 | 38.56 ± 4.83 | 0.632 |
Serum AFP > 400 ng/mL (%) | 4(19.0%) | 8(19.0%) | 0.734 | 13(31.0%) | 0.316 |
Number of tumor ≥ 2 (%) | 17(81.0%) | 33(78.6%) | 0.912 | 33(78.6%) | 0.912 |
Tumor size (mean ± SD , cm) | 4.43 ± 0.73 | 4.42 ± 2.2 | 0.980 | 4.83 ± 2.33 | 0.319 |
